Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shot up 3.4% during trading on Thursday . The company traded as high as $63.00 and last traded at $61.77, with a volume of 320,500 shares. The stock had previously closed at $59.74.

A number of brokerages have commented on ANIP. Citigroup Inc. raised ANI Pharmaceuticals to an “outperform” rating and set a $65.00 price objective for the company in a report on Tuesday, July 19th. Oppenheimer Holdings Inc. upped their target price on ANI Pharmaceuticals from $65.00 to $71.00 and gave the company an “outperform” rating in a report on Friday, August 5th. Zacks Investment Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 6th. Guggenheim reaffirmed a “buy” rating and issued a $80.00 target price (up from $65.00) on shares of ANI Pharmaceuticals in a report on Friday, August 5th. Finally, Raymond James Financial Inc. assumed coverage on ANI Pharmaceuticals in a report on Wednesday, June 22nd. They issued a “strong-buy” rating and a $68.00 target price for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $64.00.

The company’s 50-day moving average is $62.94 and its 200-day moving average is $49.21. The stock has a market cap of $707.19 million and a price-to-earnings ratio of 72.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.34. The company earned $31.30 million during the quarter, compared to analysts’ expectations of $27.63 million. The business’s quarterly revenue was up 60.5% on a year-over-year basis. During the same quarter last year, the business earned $0.55 earnings per share. Analysts expect that ANI Pharmaceuticals Inc. will post $4.12 EPS for the current year.

In other news, VP Robert W. Schrepfer sold 12,500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $67.06, for a total transaction of $838,250.00. Following the completion of the transaction, the vice president now directly owns 17,362 shares in the company, valued at $1,164,295.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Arthur Przybyl sold 37,455 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the transaction, the insider now owns 200,788 shares of the company’s stock, valued at $13,446,772.36. The disclosure for this sale can be found here.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.